Ascidian, Lilly strike RNA editing deal for kidney diseases
Bottom line
Ascidian Therapeutics and Eli Lilly have signed a global research collaboration and licensing deal to develop RNA exon editing therapies for undisclosed monogenic kidney diseases, with the option to expand to additional targets. The agreement could be worth up to about $1.9 billion in upfront, milestone, and commercial payments, plus tiered royalties. Ascidian will handle discovery and selected preclinical work, while Lilly takes over additional preclinical development, clinical development, manufacturing, and commercialization. The deal builds on growing interest in Ascidian’s RNA exon editing platform, which aims to rewrite RNA using the cell’s native splicing machinery rather than permanently altering DNA. (prnewswire.com)
Why it matters: While this is a human biopharma deal, it’s relevant to veterinary professionals because it signals continued momentum behind programmable RNA medicines for inherited disease. Ascidian’s approach is designed to replace whole mutated exons at the RNA level, a strategy that could be especially important for diseases involving large genes, many different mutations, or narrow therapeutic windows. For veterinary teams tracking translational genetics, rare disease therapeutics, and future advanced biologics, the partnership is another sign that large drugmakers see RNA editing as more than a niche platform. (prnewswire.com)
What to watch: Watch for disclosure of the first kidney targets, any preclinical proof-of-concept data, and whether Lilly expands the collaboration beyond the initial renal programs. (prnewswire.com)
Ascidian Therapeutics has landed another major validation for its RNA exon editing platform, this time through a global collaboration with Eli Lilly focused on devastating monogenic kidney diseases. Announced June 3, 2026, the agreement gives Lilly exclusive, target-specific rights to use Ascidian’s technology for undisclosed kidney disease targets and could bring Ascidian up to roughly $1.9 billion in upfront, development, regulatory, and commercial milestone payments, along with tiered royalties on worldwide sales. (prnewswire.com)
The partnership fits a broader pattern for both companies. Ascidian launched in 2022 around the idea of “rewriting” RNA rather than editing DNA directly, positioning its platform as a way to restore normal protein production without permanent genomic change. In 2024, the company said the FDA cleared its first IND for ACDN-01 in Stargardt disease and other ABCA4 retinopathies, marking an early regulatory milestone for RNA exon editing. That same year, Roche also partnered with Ascidian in a deal reportedly worth up to $1.8 billion, suggesting growing pharma interest in the platform. (prnewswire.com)
Under the new Lilly deal, Ascidian will lead discovery and selected preclinical activities, while Lilly will assume responsibility for additional preclinical work, clinical development, manufacturing, and commercialization. The companies haven’t disclosed the specific kidney disease targets, but they described them as monogenic disorders, with an option to expand to more targets over time. According to the companies, the platform is designed to use the cell’s natural RNA splicing machinery and avoid introducing foreign enzymes or modifying genomic DNA directly. That matters because kidney disease genetics can be highly heterogeneous, and inherited renal disorders include hundreds of conditions that affect kidney structure or function. (prnewswire.com)
Industry coverage adds some useful color on why Lilly may have been interested. Fierce Biotech reported that Ascidian executives have been selective about where they think the technology can be truly differentiated, highlighting use cases such as genes too large for a single AAV vector, diseases with high mutational variance, narrow therapeutic indexes, and dominant disorders where one intervention might both reduce toxic protein and restore normal protein. In comments to Fierce, Ascidian Chief Scientific Officer Robert Bell said Lilly’s experience in genetic medicines and renal disease gave the biotech confidence the programs could be advanced effectively. (fiercebiotech.com)
Why it matters: For veterinary professionals, this is not a practice-changing animal health story, but it is a meaningful translational signal. Veterinary medicine increasingly intersects with comparative genomics, inherited disease research, and advanced therapeutics, especially in referral, academic, and specialty settings. A platform that can swap out whole mutated exons at the RNA level could, in principle, offer a different path than conventional gene replacement or DNA editing for disorders with many causative variants or genes too large for standard delivery systems. Even if these kidney programs remain firmly in human medicine for now, the scientific and regulatory progress around RNA editing may influence how future companion animal genetic therapies are designed, discussed, and evaluated. (pmc.ncbi.nlm.nih.gov)
The other takeaway is strategic. Lilly has been active in business development across advanced modalities, and this deal shows the company is willing to place another sizable bet on next-generation genetic medicine, this time in renal disease. For smaller platform companies, that’s a sign that pharma still sees value in differentiated editing technologies despite a tougher financing environment and the long timelines typical of rare disease development. (biospace.com)
What to watch: The next milestones will be target disclosure, preclinical data showing efficient delivery and editing in kidney tissue, and any future regulatory signals as programs move toward the clinic. It will also be worth watching whether Lilly uses the option to broaden the partnership, which would be a strong indicator of early confidence in the platform’s performance in renal disease models. (prnewswire.com)